We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-19.07%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$129M
AUM Growth
-$22M
Cap. Flow
-$11.1M
Cap. Flow %
-8.62%
Top 10 Hldgs %
47.53%
Holding
65
New
8
Increased
16
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$3.31M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.19M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.82M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$994K
5
SDS icon
ProShares UltraShort S&P500
SDS
+$967K

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$10.7M
2
GILD icon
Gilead Sciences
GILD
+$2.74M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$1.5M
4
XNCR icon
Xencor
XNCR
+$1.32M
5
AMGN icon
Amgen
AMGN
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 73.12%
2 Miscellaneous 26.17%
3 Real Estate 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$81.9B
$22.1M 17.11%
+200,000
New +$20.7M
BMY icon
2
Bristol-Myers Squibb
BMY
$137B
$4.92M 3.81%
77,100
– –
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
$4.89M 3.78%
106,358
+15,048
+16% +$546K
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$31.7B
$4.87M 3.77%
77,593
+27,371
+55% +$1.82M
MRK icon
5
Merck
MRK
$369B
$4.76M 3.68%
94,320
– –
AMGN icon
6
Amgen
AMGN
$236B
$4.08M 3.15%
27,184
-8,589
-24% -$1.28M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.6B
$3.98M 3.08%
48,260
+4,390
+10% +$357K
CELG
8
DELISTED
Celgene Corp
CELG
$3.96M 3.06%
39,596
-8,360
-17% -$861K
NKTR icon
9
Nektar Therapeutics
NKTR
$2.55B
$3.96M 3.06%
19,211
-4,028
-17% -$774K
IONS icon
10
Ionis Pharmaceuticals
IONS
$10.4B
$3.92M 3.03%
96,808
-5,651
-6% -$230K
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$3.86M 2.98%
109,922
-17,166
-14% -$577K
INCY icon
12
Incyte
INCY
$25.9B
$3.75M 2.9%
51,677
+3,632
+8% +$271K
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
$3.54M 2.73%
25,405
-7,564
-23% -$1.11M
ILMN icon
14
Illumina
ILMN
$34.4B
$3.52M 2.72%
22,337
-940
-4% -$144K
ALKS icon
15
Alkermes
ALKS
$8.2B
$3.5M 2.7%
102,277
+14,862
+17% +$587K
MTD icon
16
Mettler-Toledo International
MTD
$28.2B
$3.27M 2.53%
9,500
-200
-2% -$64.4K
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$139B
$3.27M 2.53%
41,137
-525
-1% -$47.5K
PFE icon
18
Pfizer
PFE
$160B
$3.26M 2.52%
+115,940
New +$3.31M
REGN icon
19
Regeneron Pharmaceuticals
REGN
$83.2B
$3.22M 2.49%
8,929
-1,785
-17% -$736K
QGENF
20
DELISTED
QIAGEN NV
QGENF
$3.02M 2.33%
135,000
-25,000
-16% -$559K
BIIB icon
21
Biogen
BIIB
$32.7B
$2.9M 2.24%
11,125
+643
+6% +$170K
BIB icon
22
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$2.63M 2.04%
64,462
+49,543
+332% +$2.19M
EPZM
23
DELISTED
Epizyme, Inc
EPZM
$2.3M 1.78%
189,564
+53,937
+40% +$546K
AZN icon
24
AstraZeneca
AZN
$255B
$2.23M 1.72%
39,550
+15,000
+61% +$901K
AGIO icon
25
Agios Pharmaceuticals
AGIO
$2.05B
$2.07M 1.6%
51,000
+17,000
+50% +$727K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opus Point Partners Management held 65 positions worth $129M, down 15% from $151M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $11.1M in Q1 2016, closing 13 positions and reducing 26 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $10.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Pfizer worth $3.26M.

  • Opus Point Partners Management's largest Q1 2016 buy was Pfizer: 115,940 shares worth $3.26M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2016, an estimated $2.19M increase.
  • Opus Point Partners Management's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $2.74M.
  • Opus Point Partners Management fully exited iShares Biotechnology ETF in Q1 2016, selling an estimated $10.7M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $129M portfolio in Q1 2016.
  • Opus Point Partners Management opened 8 new positions and closed 13 in Q1 2016.
  • Opus Point Partners Management's portfolio value fell 15% quarter-over-quarter to $129M.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.